Yeztugo (lenacapavir) / Gilead - LARVOL DELTA

A Scientometric Mapping of Global Lenacapavir and HIV Research: Dynamism, Visualization, and Emerging Patterns. (PubMed, Int J Prev Med) - "The findings are useful for identifying key sources and authors, facilitating future research and collaboration. The findings highlight how crucial international collaboration is for driving progress in scientific research and tackling worldwide health issues."

Journal • Human Immunodeficiency Virus • Infectious Disease

PrEP4U: Assessing the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Follow-up Choice on PrEP Persistence (clinicaltrials.gov) - P=N/A | N=400 | Recruiting | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Feb 2027 ➔ Jul 2027 | Trial primary completion date: Feb 2027 ➔ Jul 2027

Enrollment open • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

Structural basis of lenacapavir-induced HIV-1 capsid defects during virion maturation. (PubMed, Nat Commun) - "Functionally, viruses produced in the presence of LEN exhibit markedly reduced infectivity, low reverse transcription activity, and poor integration. Taken together, these findings provide mechanistic insights into the late-phase action of LEN and provide key directions for the design of future inhibitors."

Journal • Human Immunodeficiency Virus • Infectious Disease

Descriptive Evaluation of a Medical Affairs–Led Educational Resource to Support Healthcare Providers in the Implementation of Lenacapavir for HIV PrEP (IDWeek 2026) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Lenacapavir for HIV PrEP: Early Real-World Implementation Insights on Uptake, Patient Pathways, and Injectable Transition Outcomes at a Multi-Site U.S. Clinic Network (IDWeek 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

High Incidence of HIV in Countries Excluded from Lenacapavir Access Programme (IDWeek 2026) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Implementation and Uptake of Lenacapavir Long-acting Injectable PrEP at Duke University Hospital (IDWeek 2026) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Real-World Evaluation of Patient Utilization and Satisfaction with Lenacapavir Injections for HIV Pre-Exposure Prophylaxis (IDWeek 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

Real-World Experience with Injectable Lenacapavir Regimens in Patients with HIV-1: A Descriptive Study (IDWeek 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

Baseline Characteristics and Substance Use Among People Who Inject Drugs (PWID) with Evidence of Active Use in HPTN 103/PURPOSE 4: a Phase 2 Study of Twice-Yearly Subcutaneous (SC) Lenacapavir (LEN) for Pre-exposure Prophylaxis (PrEP) (IDWeek 2026) - No abstract available

P2 data • Human Immunodeficiency Virus • Infectious Disease

Low Incidence of Hepatitis B (HBV) Infection Among People Receiving Lenacapavir (LEN) or Tenofovir-Based HIV Pre-exposure Prophylaxis (PrEP) in PURPOSE 1 and PURPOSE 2 (IDWeek 2026) - No abstract available

Hepatitis B • Human Immunodeficiency Virus • Infectious Disease

Early Real-World Adoption Patterns of Long-Acting Lenacapavir for HIV PrEP in the United States (June 2025–March 2026) (IDWeek 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

Squabbles Among Friends: Pushing the Envelope on HIV Treatment and Prevention (IDWeek 2026) - "Organized by Co-Organizing Groups: N/A Learning Objectives: At the conclusion of this session, participants will be able to:Apply emerging clinical questions in HIV treatment and preventionRecognize the evidence for alternative PrEP strategies in persons assigned female at birthEvaluate the benefits and risks of use of lenacapavir in people living with HIV with uncertain treatment resistance"

Human Immunodeficiency Virus • Infectious Disease

Lenacapavir resistance surveillance in full-length HIV-1 proviral DNA and circulating RNA: Major RAMs are rare and absent in intact proviral DNA. (PubMed, J Clin Virol) - "Major LEN RAMs were rare in both proviral DNA and circulating RNA and were absent in intact subtype B proviral DNA. Although p24 was highly conserved, recurrent substitutions followed non-random patterns across compartments. These findings support cautious interpretation of gag variation detected in proviral DNA alone and do not provide evidence to support routine baseline capsid resistance testing before LEN use where such testing is not otherwise indicated."

Journal • Human Immunodeficiency Virus • Infectious Disease

First virological control after >30 years of antiretroviral therapy in extensively drug-resistant HIV: potential role of lenacapavir plus ibalizumab. (PubMed, J Antimicrob Chemother) - No abstract available

Journal • Human Immunodeficiency Virus • Infectious Disease

Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. (PubMed, J Med Virol) - "In one of these 3 persistently viremic PWH, a dual-injectable rescue regimen combining lenacapavir and cabotegravir achieved viral suppression at 33 months with maintenance through the end of follow-up, bringing the success rate to 9 out of 11 (82%) among PWH who were viremic at baseline. A dual-injectable rescue regimen may represent a last-resort option in selected complex cases. Similar real-world studies should be expanded, and adherence support should be strengthened."

Journal • Real-world evidence • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4

Lenacapavir: Gilead is urged to change price after NHS rejects HIV drug owing to cost. (PubMed, BMJ) - No abstract available

Journal • Human Immunodeficiency Virus • Infectious Disease

Structure-guided discovery of HIV-1 capsid inhibitors: From diverse binding sites to resistance-resilient antiviral strategies. (PubMed, Eur J Med Chem) - "This review covers 2020-2026 advances in CA-targeted drug discovery: high-resolution CA structures; allosteric regulation by host metabolite IP6; medicinal chemistry optimization of PF74 derivatives via scaffold hopping and conformational restriction to enhance potency and metabolic stability; the development and clinical use of lenacapavir-the first ultra-long-acting CA inhibitor-and mechanisms of resistance (e.g., M66I); emerging inhibitors against resistant strains and cryptic binding sites; and current challenges. We also briefly discuss emerging approaches such as AI-driven design and PROTACs (Proteolysis-Targeting Chimeras), and highlight long-acting combination regimens as a promising path toward an HIV-1 functional cure."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease • Targeted Protein Degradation

HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy. (PubMed, J Antimicrob Chemother) - "These findings demonstrate DTG resistance in both adult and paediatric participants with virological failure with G118R emerging as a prominent resistance pathway. No known primary LEN resistance mutation was detected in the assessable capsid sequences, although phenotypic susceptibility and clinical outcomes were not evaluated. These findings support continued surveillance of integrase and capsid resistance as long-acting antiretroviral strategies expand."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

FDAs new approval: yeztugo (lenacapavir): A longer lasting avenue against HIV. (PubMed, J Pak Med Assoc) - No abstract available

Journal • Human Immunodeficiency Virus • Infectious Disease

Lenacapavir binding to immature Gag induces giant virions and causes protease-dependent inhibition of viral release. (PubMed, Proc Natl Acad Sci U S A) - "Although LENiVLPs retained membrane fusion capability, they were noninfectious owing to postentry defects that prevented viral replication. Thus, LEN binds to the precursor Gag and promotes aberrant particle formation, offering insights that could guide the development of next-generation LEN-based therapeutics targeting the late stages of the viral life cycle."

Journal • Human Immunodeficiency Virus • Infectious Disease

Lenacapavir allosterically remodels the HIV-1 capsid. (PubMed, Sci Adv) - "At the molecular level, LEN alters the noncovalent bonding interactions between capsid subunits and reduces local lattice curvature. We propose a stress-strain model to rationalize how LEN remodels HIV-1 capsid structure and thereby impairs the replication capacity of the virus."

Journal • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Diseases • Orthopedics

Evaluating the combination of bictegravir and lenacapavir as a single tablet option for HIV. (PubMed, Expert Opin Pharmacother) - "Future HIV therapy will evolve toward increasingly personalized treatment integrating daily oral, extended-interval oral, and long-acting injectables. Within this evolving paradigm, LEN/BIC will expand therapeutic options and advance patient-centered HIV care."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease

Clinical Resistance to Lenacapavir During Treatment of HIV Infection: A Review. (PubMed, Viruses) - "In contrast, no cases of viral rebound with resistance to LEN have been observed in virologically suppressed PWH switching to the once-daily single-tablet regimen (STR) combining LEN with the integrase strand-transfer inhibitor (INSTI) bictegravir after up to 48 weeks in two Phase 3 studies, and for >3 years in Phase 2. Similarly, no resistance to LEN has been observed after up to 96 weeks in the Phase 2 study of once-weekly regimen of the deoxyadenosine analog RT inhibitor islatravir + LEN...Overall, resistance to LEN in regimens using synchronous dosing (daily or weekly oral, or 6-monthly injectable) has been rare in clinical studies. As the use of LEN is predicted to increase in the near future with these potential new combinations, capabilities to test for capsid resistance are being developed through global commercial options as well as through regional health institutions."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease

Comparing carbon emissions from oral tenofovir disoproxil fumarate/emtricitabine for preexposure prophylaxis and long-acting injectables for HIV prevention. (PubMed, AIDS) - "Estimated greenhouse gas emissions from active pharmaceutical ingredient (API) production were compared for oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and long-acting injectable preexposure prophylaxis (PrEP) agents, cabotegravir (CAB-LA) and lenacapavir (LEN). For 2 million person-years of PrEP, TDF/FTC generated approximately 108 million kg CO2e, compared with 4.1 million kg for CAB-LA and less than 0.1 million kg for LEN. These findings suggest substantially lower emissions with long-acting agents, supporting consideration of environmental sustainability in HIV prevention strategies."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease